News
Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...
A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S’s weight loss drug while a ...
Novo Nordisk, a leading global healthcare company, has announced the signing of a MoU with Lifera, a biopharmaceutical ...
Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...
On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...
A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.
Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback